Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
暂无分享，去创建一个
M. Shipp | N. Johnson | J. Radford | P. Zinzani | P. Armand | V. Ribrag | A. Tomita | P. Brice | A. Ricart | D. Molin | M. Fanale | C. Moskowitz | A. Balakumaran | T. Vassilakopoulos | B. von Tresckow | Robert Chen | Yinghua Zhang